Imvax   Report issue

For profit Phase 2
Founded: Philadelphia PA United States (2015)

Organization Overview

First Clinical Trial
2021
NCT04485949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Imvax

Active Ingredients

Drugs in Phase 2 Trials (2)

igv-001 (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2